Evaluation of the effect of L-carnitine on the prevention of drug induced hepatitis

Evaluation of the effect of L-carnitine on the prevention of PEG-Asparaginase-induced hepatitis in patients with acute lymphoblastic leukemia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190202042583N4

Enrollment

Registered

2023-11-06

Start date

2023-03-21

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphoblastic Leukemia. Acute lymphoblastic leukemia [ALL]

Interventions

Intervention 1: Intervention group: Before entering the induction phase, preliminary tests are taken from each patient according to the protocol, which are recorded daily until the fourteenth day afte

Eligibility

Sex/Gender

All

Age

1 Months to 18 Years

Inclusion criteria

Inclusion criteria: getting acute lymphoblastic leukemia normal enzyme levels at the beginning of the study

Exclusion criteria

Exclusion criteria: underlying liver disease underlying metabolic disease involving the liver (galactosemia-tyrosinemia-...) Viral hepatitis Use of hepatotoxic drugs Elevation of bilirubin or liver transaminases above normal values before the start of the study Contraindication or allergy to L-carnitine

Design outcomes

Primary

Measure	Time frame
Drug induced Hepatitis. Timepoint: before receiving the drug to 14 days after receiving PEG-Asparaginase. Method of measurement: by the clinical supervisor accompanying the plan and according to the criteria of the World Health Organization.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad NaderiSorki

Mazandaran University of Medical Sciences

dr.naderisorki@mazums.ac.ir+98 11 3334 7837

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026